Safety Assessment of Tamoxifen and Toremifen

ONCOLOGY

Volumn 11, Issue 5 SUPPL. 4, 1997, Pages 41-47

  Williams, Gary M ^a   Jeffrey, Alan M ^b  

^a Department of Medical Sciences ^*

^b AMERICAN HEALTH FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOMIFENE; DIETHYLSTILBESTROL; DROLOXIFENE; TAMOXIFEN; TAMOXIFEN CITRATE; TOREMIFENE;

ANIMAL EXPERIMENT; BREAST CANCER; CARCINOGENICITY; DRUG SAFETY; DRUG STRUCTURE; ENDOMETRIUM CANCER; GENOTOXICITY; HAMSTER; HUMAN; MOUSE; NONHUMAN; RAT; REVIEW;

EID: 0030912411     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (81)

1. Kangas L: Development and Biochemical Pharmacology of Toremifene, an Antiestrogenic Anticancer Drug. Serioffset, Turku, Finland, 1990.
2. Lerner LJ, Jordan VC: Development of antiestrogens and their use in breast cancer Eighth Cain Memorial Award lecture. Cancer Res 50:4177-4189, 1990.
3. Early Breast Cancer Trialists Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy: 133 randomized trials involving 13,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339:71-85, 1999.
4. Pyrhonen SO: Phase III studies of toremifene in metastatic breast cancer. Breast Cancer Res Treat 16 (suppl):S41-S46, 1990.
5. International Agency for Research on Cancer: Tamoxifen in IARC Monographs on the Evaluation of Carcinogenic Risks to Humans: Some Pharmaceutical Drugs, vol 66, pp 253-387. Lyon, IARC, 1996.
6. Pitot HC: The tamoxifen controversy - clinical chemopreventive agent and experimental carcinogen. Proc Soc Exp Biol Med 208:139-140, 1995.
7. Jordan VC, Morrow M: Should clinicians be concerned about the carcinogenic potential of tamoxifen? Eur J Cancer 30A:1714-1721, 1994.
8. King CM: Tamoxifen and the induction of cancer. Carcinogenesis 16:1449-1454, 1995.
9. Williams GM, Iatropoulos MJ, Djordjevic MV, et al: The triphenylethylene drug tamoxifen is a strong liver carcinogen in the rat. Carcinogenesis 14:315-317, 1993.
10. Hirsimäki P, Hirsimäki Y, Nieminen L, et al: Tamoxifen induces hepatocellular carcinoma in rat liver: A 1-year study with two antiestrogens. Arch Toxicol 67:49-54, 1993
11. Greaves P, Goonetilleke R, Nunn G, et al: Two-year carcinogenicity study of tamoxifen in Alderley park Wistar-derived rats. Cancer Res 53:3919-3924, 1993.
12. Hard GC, Iatropoulos MJ, Jordan K, et al: Major difference in the hepatocarcinogenicity and DNA adduct forming ability between toremifene and tamoxifen in female Crl:CD(BR) rats. Cancer Res 53:4534-4541, 1993.
13. Vancutsem PM, Lazarus P, Williams GM: Frequent and specific mutations of the rat p53 gene in hepatocarcinomas induced by tamoxifen. Cancer Res 54:3864-3867, 1994.
14. Osborne MR, Hewer A, Hardcastle IR, et al: Identification of the major tamoxifen-deoxyguanosine adduct formed in the liver DNA of rats treated with tamoxifen. Cancer Res 56:66-71, 1996.
15. Yager JD, Roebuck BD, Paluszcyk TL, et al: Effects of ethinyl estradiol and tamoxifen on liver DNA turnover and new synthesis and appearance of gamma glutamyl transpeptidase-positive foci in female rats. Carcinogenesis 7:2007-2014, 1986.
16. Kim DJ, Han BS, Ahn B, et al: Promotion potential of tamoxifen on hepatocarcinogenesis in female SD or F344 rats initated with diethylnitrosamine. Cancer Lett 104:13-19, 1996.
17. Dragan VP, Vaughan J, Jordan VC, et al: Comparison of the effects of tamoxifen and toremifene on liver and kidney tumor promotion in female rats. Carcinogenesis 16:2733-2741, 1995
18. Dragan YP, Fahey S, Street K, et al: Studies of tamoxifen as a promoter of hepatocarcinogenesis in female Fischer F344 rats. Breast Cancer Res Treat 31:11-25, 1994.
19. Tucker MJ, Adam HK, Patterson JS, in Laurence DR, McLean DEM, Wetherall M (eds): Safety Testing of New Drugs: Laboratory Predictions and Clinical Performance, pp 125-161. London, Academic Press, 1984.
20. Iatropoulos M: Comparative histokinetic and xenodynamic considerations in toxicity, in Welling PG, de la Inglesia FA (eds). Drug Toxicokinetics, pp 245-266. New York. Marcel Dekker, 1993.
21. Robinson SP, Langan-Fahey L, Johnson DA, et al: Metabolites, pharmacodynamics and pharmacokinetics of tamoxifen in rats and mice compared to the breast cancer patient, Drug Metab Disp 19:36-43, 1991.
22. Karlsson S, Hirsimäki Y, Mäntylä L, et al: A two-year dietry carcinogenicity study of the antiestrogen toremifene in Sprague-Dawley rats. Drug Chem Toxicol 19:245-266, 1996.
23. Kangas L: Agonistic and antagonistic effects of antiestrogens in different target organs. Acta Oncol 31:143-146, 1992.
24. Dragan YP, Xu YD, Pitot HC: Tumor promotion as a target for estrogen/antiestrogen effects in rat hepatocarcinogenesis. Prevent Med 20:15-26, 1991.
25. Han XL, Liehr JG: Induction of covalent DNA adducts in rodents by tamoxifen. Cancer Res 52:1360-1363, 1992.
26. White IN, De Matteis F, Davies A, et al: Genotoxic potential of tamoxifen and analogues in female Fischer F344/n rats, DBA/2 and C57BL/6 mice and in human MCL-5 cells. Carcinogenesis 13:2197-2203, 1992.
27. Montandon F, Williams GM: Comparison of DNA reactivity of poly- phenylethylene hormonal agents diethylstilbestrol, tamoxifen and toremifene in rat and hamster liver. Arch Toxicol 68:272-275, 1994.
28. Mani C, Kupfer D: Cytochrome P450 mediated activation and irreversible binding of the antiestrogen tamoxifen to proteins in the rat and human liver: Possible involvement of flavin-containing monoxygenases in tamoxifen activation. Cancer Res 51:6052-6058, 1991.
29. Hemminki K, Widlak P, Hou SM: DNA adducts caused by tamoxifen and toremifene in human microsomal system and lymphocytes in vitro. Carcinogenesis 16:1661-1664, 1995.
30. 14C]tamoxifen to liver microsomes and the forms of cytochrome P450 involved. Biochem Pharmacol 49:1035-1042, 1995.
31. Phillips DH, Hewer A, White IN, Farmer PB: Co-chromatography of a tamoxifen epoxidedeoxyguanylic acid adduct with a major DNA adduct formed in the livers of tamoxifen-treated rats. Carcinogenesis 15:793-795, 1994.
32. Potter GA, McCague R, Jarman M: A mechanistic hypothesis for DNA adduct formation by tamoxifen following hepatic oxidative metabolism. Carcinogenesis 15:439-442, 1994.
33. Moorthy B, Sriram P, Pathak DN, et al: Tamoxifen metabolic activation: Comparison of DNA adducts formed by microsomal and chemical activation of tamoxifen and 4-hydroxytamoxifen with DNA adducts formed in vivo. Cancer Res 56:53-57, 1996.
34. 5-ethyl]tamoxifen. Carcinogenesis 16:683-688, 1995.
35. 5-ethyl]-tamoxifen implicates a-hydroxylation of the ethyl group as a major pathway of tamoxifen activation to a liver carcinogen. Carcinogenesis 15:1487-1492, 1994.
36. Phillips DH, Carmichael PL, Hewer A, et al: Activation of tamoxifen and its metabolite a-hydroxytamoxifen to DNA-binding products: Comparisons between human, rat and mouse hepatocytes. Carcinogenesis 17:89-94, 1996.
37. Davies AM, Martin EA, Jones RM, et al: Peroxidase activation of tamoxifen and toremifene resulting in DNA damage and covalently bound protein adducts. Carcinogenesis 16:539-545, 1995
38. Pathak DN, Pongracz K, Bodell WJ: Microsomal and peroxidase activation of 4- hydroxytamoxifen to form DNA adducts: Comparison with DNA adducts formed in Sprague-Dawley rats treated with tamoxifen. Carcinogenesis 16:11-15, 1995.
39. Poon GK, Walter B, Lønning M, Horton MN, et al: Identification of tamoxifen metabolites in human HEP G2 cell line, human liver homogenate, and patients on long-term therapy for breast cancer. Drug Metab Disp 23:377-382, 1995.
40. Sargent LM, Dragan YP, Sattler C, et al: Induction of hepatic aneuploidy in vivo by tamoxifen, toremifene and idoxifene in female Sprague-Dawley rats. Carcinogenesis 17:1051-1056, 1966.
41. Vijayalaxmi KK, Rai SP: Studies on the genotoxicity of tamoxifen citrate in mouse bone marrow cells Mutat Res 368:109-114, 1996.
42. Styles JA, Davies A, Lim CK, et al: Genotoxicity of tamoxifen, tamoxifen epoxide and toremifene in human lymphoblastoid cells containing human cytochrome P450s Carcinogenesis 15:5-9, 1994.
43. Comoglio A, Gibbs AH, White INH, et al: Effects of tamoxifen feeding on metabolic activation of tamoxifen by the liver of Rhesus monkey: Does liver accumulation of inhibitory metabolites pretect from tamoxifen-dependent genotoxicity and cancer? Carcinogenesis 17:1687-1693, 1996.
44. Hyder SM, Stancel GM, Chippetta C, et al: Uterine expression of vascular endothelial growth factor is increased by estradiol and tamoxifen. Cancer Res 56:3954-3960, 1996.
45. Kuramochi H. Conformational studies and electronic structures of tamoxifen and toremifine and their alylic carbocations proposed as reactive intermediates leading to DNA adduct formation. J Med Chem 39:2877-2886, 1996.
46. Cunningham A, Klopman G, Rosenkranz HS: A study of the structural basis of the carcinogenicity of tamoxifen, toremifene and their metabolites. Mutat Res 349:85-94, 1996.
47. Webb P, Lopez GN, Uht RM, et al: Tamoxifen activation of the estrogen receptor/AP-1 pathway: Potential origin for the cell-specific estrogen-like effects of antiestrogens. Mol Endrocrinol 9:443-456, 1995.
48. Yang NN, Venugopalan M, Hardikar S, et al: Identification of an estrogen response element activated by metabolites of 17 a-estradiol and raloxifene. Science 273:1222-1225, 1996.
49. Kuiper GG, Enmark E, Pelto-Huikko M, et al: Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA 93:5925-5930, 1996
50. Killackey MA, Hakes TB, Pierce VK: Endometrial adenocarcinoma in breast cancer patients receiving antiestrogens. Cancer Treat Rep 69:237-238, 1985.
51. Hardell L: Tamoxifen as risk factor for carcinoma of corpus uteri (letter). Lancer 2:563, 1988.
52. Fornander T, Cedermark B, Mattsson A, et al: Adjuvant tamoxifen in early breast cancer: Occurrence of new primary cancers. Lancet 2:117-120, 1989.
53. Rutqvist LE, Johansson H, Signomklao T, et al: Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies: Stockholm Breast Cancer Study Group. J Natl Cancer Inst 87:645-651, 1995.
54. Curtis RE, Boice JD Jr, Shriner DA, et al: Second cancers after adjuvant tamoxifen therapy for breast cancer. J Natl Cancer Inst 88:832-834, 1996.
55. Muhlemann K, Cook LS, Weiss NS: The incidence of hepatocellular carcinoma in US white women with breast cancer after the introduction of tamoxifen in 1977. Breast Cancer Res Treat 30:201-204, 1994.
56. Atkin CD: Re: Second cancers after adjuvant tamoxifen therapy for breast cancer. J Natl Cancer Inst 88:1496-1497, 1996.
57. Curtis RE, Boice JD, Shriner DA, et al: Re: Second cancers after adjuvant tamoxifen therapy for breast cancer (response) J Natl Cancer Inst 88:1497-1499, 1996.
58. Pathak DN, Bodell WJ: DNA adduct formation by tamoxifen with rat and human liver microsomal activation systems. Carcinogenesis 15:529-532, 1994.
59. 32P-postlabelled DNA adducts in liver obtained from women treated with tamoxifen. Carcinogenesis 16:1651-1654, 1995.
60. Carmichael PL, Ugwumadu AH, Neven P, et al: Lack of genotoxicity of tamoxifen in human endometrium. Cancer Res 56:1475-1479, 1996.
61. Phillips DH, Hewer A, Grover PL, et al: Tamoxifen does not form detectable DNA adducts in white blood cells of breast cancer patients. Carcinogenesis 17 1149-1152, 1996.
62. Hemminki K, Rajantemi H, Lindahl B, et al: Tamoxifen-induced DNA adducts in endumetrial samples from breast cancer patients. Cancer Res 56:4374-4377, 1996.
63. Williams GM, Weisburger JH: Chemical Carcinogenesis, in Klaassen CD, Amdur MO, Doull J (eds): Toxicology, 4th ed, pp 127-200. New York, McGraw-Hill, 1991.
64. Lim CK, Yuan ZX, Lamb JH, et al: A comparative study of tamoxifen metabolism in female rat, mouse and human liver microsomes. Carcinogenesis 15:589-593, 1994
65. Hollstein M, Sidransky D, Vogelstein B, et al: p53 mutations in human cancers. Science 253:49-53, 1991.
66. Harris CC: p53 tumor suppressor gene: From the basic research laboratory to the clinic - an abridged historical perspective. Carcinogenesis 17 1187-1198, 1996.
67. Harris CC: Structure and function of the p53 tumor supressor gene: Clues for rational cancer theraputic strategies J Natl Cancer Inst 88:1442-1455, 1996.
68. Kihana T, Hamada K, Inoue Y, et al: Mutation and allelic loss of the p53 gene in endometrial carcinoma: Incidence and outcome in 92 surgical patients. Cancer 76:72-78, 1995
69. Riethdorf L, Bergemann C, Reithdorf S, et al: Comparison of benign and malignant endometrial lesions for their p53 state, using immunohistochemistry and temperature-gradient gel electrophoresis. Virchows Arch 428:47-51, 1996.
70. Niwa K, Itoh M, Murase T, et al: Alteration of p53 gene in ovarian carcinoma: Clinicopathological correlation and prognostic significance. Br J Cancer 70:1191-1197, 1994.
71. Schneider J, Rubio MP, Barbazan MJ, et al: P-glycoprotein, HER-2/neu, and mutant p53 expression in human gynecologic tumors. J Natl Cancer Inst 86-850-855, 1994.
72. Naito M, Satake M, Sakai E, et al: Detection of p53 gene mutations in human ovarian and endometrial cancers by polymerase chain reaction-single strand conformation polymorphism analysis Jpn J Cancer Res 83:1030-1036, 1992.
73. Risinger JI, Dent GA, Ignar-Trowbridge D, et al: p53 gene mutations in human endometrial carcinoma. Mol Carcinogenesis 5:250-253, 1992.
74. Williams GM, Iatropoulos MJ, Hard GC: Long-term prophylactic use of tamoxifen: Is it safe? Eur J Cancer Prev 1:386-387, 1992.
75. Bulbrook RD: Long term adjuvant therapy for primary breast cancer (editorial). Br Med J 312:389-390, 1996.
76. Edmonson JH: Whither tamoxifen (editorial). Gynecol Oncol 62:1-3, 1996.
77. Greenspan EM: Tamoxifen for the prevention of breast cancer (letter). Am J Med 100:665, 1996.
78. Fisher B: Commentary on endometrial cancer deaths in tamoxifen-treated breast cancer patients. J Clin Oncol 14:1027-1039, 1996.
79. Cai Q, Wei H: In vivo formation of DNA-adducts in mouse skin DNA by tamoxifen. Cancer Lett 92:187-192, 1995
80. 32P-postlabelling in three rat strains exposed to dietary tamoxifen: The relationship between cell proliferation and liver tumor formation. Carcinogenesis 16:1299-1304, 1995.
81. Sargent LM, Dragan YP, Bahnub N, et al: Tamoxifen induces hepatic aneuploidy and mitotic spindle disruption after a single in vivo administration to female Sprague-Dawley rats. Cancer Res 54:3357-3360, 1994.